Gary S Marshall

Summary

Affiliation: University of Louisville
Country: USA

Publications

  1. ncbi request reprint Prolonged and recurrent fevers in children
    Gary S Marshall
    University of Louisville School of Medicine, 571 S Floyd St, Suite 321, Louisville, KY 40202, USA Electronic address
    J Infect 68:S83-93. 2014
  2. doi request reprint Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age
    Gary S Marshall
    University of Louisville School of Medicine, Louisville, KY 40202, USA
    Pediatr Infect Dis J 32:662-8. 2013
  3. doi request reprint Common variable immunodeficiency presenting with persistent parvovirus B19 infection
    Sarah T M Adams
    Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky, Louisville, KY 40202, USA
    Pediatrics 130:e1711-5. 2012
  4. ncbi request reprint Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United Sta
    Gary S Marshall
    University of Louisville, Louisville, KY, USA
    Hum Vaccin 7:258-64. 2011
  5. ncbi request reprint Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age
    Gary S Marshall
    Department of Pediatrics, University of Louisville School of Medicine, Louisville, KY 40202, USA
    Pediatr Infect Dis J 29:469-71. 2010
  6. doi request reprint Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants
    Kristina A Bryant
    University of Louisville, Louisville, Kentucky, USA
    Pediatrics 127:e1375-85. 2011
  7. doi request reprint Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers
    Kristina A Bryant
    Department of Pediatrics, University of Louisville School of Medicine, 571 South Floyd Street, Suite 321, Louisville, KY 40202, USA
    Expert Rev Vaccines 10:941-50. 2011

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Prolonged and recurrent fevers in children
    Gary S Marshall
    University of Louisville School of Medicine, 571 S Floyd St, Suite 321, Louisville, KY 40202, USA Electronic address
    J Infect 68:S83-93. 2014
    ....
  2. doi request reprint Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age
    Gary S Marshall
    University of Louisville School of Medicine, Louisville, KY 40202, USA
    Pediatr Infect Dis J 32:662-8. 2013
    ..This study assessed antibody persistence up to 5 years after vaccination...
  3. doi request reprint Common variable immunodeficiency presenting with persistent parvovirus B19 infection
    Sarah T M Adams
    Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky, Louisville, KY 40202, USA
    Pediatrics 130:e1711-5. 2012
    ..This case demonstrates that persistent parvovirus infection may be a presenting feature of humoral immune deficiency and can mimic juvenile rheumatoid arthritis. The infection may respond to immune globulin intravenous therapy...
  4. ncbi request reprint Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United Sta
    Gary S Marshall
    University of Louisville, Louisville, KY, USA
    Hum Vaccin 7:258-64. 2011
    ..A schedule of HibMenCY-TT given concomitantly with PCV7 and DTaP-HepB-IPV would be expected to protect infants against all of the targeted diseases...
  5. ncbi request reprint Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age
    Gary S Marshall
    Department of Pediatrics, University of Louisville School of Medicine, Louisville, KY 40202, USA
    Pediatr Infect Dis J 29:469-71. 2010
    ..4%, respectively. One year later, anti-PRP concentrations > or =0.15 microg/mL, and MenC and MenY bactericidal titers > or =1:8 persisted in 100%, 96.6%, and 83.8%, respectively. The safety profile of HibMenCY was comparable to Hib...
  6. doi request reprint Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants
    Kristina A Bryant
    University of Louisville, Louisville, Kentucky, USA
    Pediatrics 127:e1375-85. 2011
    ..A phase III study evaluated the immunogenicity and safety of an investigational Haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY)...
  7. doi request reprint Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers
    Kristina A Bryant
    Department of Pediatrics, University of Louisville School of Medicine, 571 South Floyd Street, Suite 321, Louisville, KY 40202, USA
    Expert Rev Vaccines 10:941-50. 2011
    ..If licensed, HibMenCY-TT not only represents an incremental option for protection against invasive Hib, but also has the potential to prevent invasive meningococcal disease without increasing the number of injections...